Zygem Strengthens its Worldwide Presence with new Distribution Agreements in Asia Pacific Markets
News May 19, 2009
ZyGEM Corp. Ltd. has announced it has entered into a number of new agreements that strengthen its market presence in the Asia Pacific region. These include distribution agreements for its innovative DNA extraction kits in China and South Korea and partnerships in New Zealand and parts of Australia to broaden the company’s product offerings in its home market.
These new agreements build on the early success of ZyGEM’s recent major distribution agreements for its DNA extraction kits in the Americas and Europe with a leading life science products distributor.
These new agreements include exclusive distribution rights for ZyGEM’s full line of DNA extraction kits-in China, through Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. (Sangon) and in South Korea, through SolGent Inc.
In addition, in New Zealand and certain parts of Australia, ZyGEM is now co-distributing custom oligonucleotides from Integrated DNA Technologies, Inc., PCR reagents from Quanta Biosciences, sample storage products from Biomatrica, Inc., and laboratory microplates from Porvair Sciences.
“ZyGEM’s recently announced distribution agreements for our DNA extraction kits in the Americas and Europe provide us with an exceptionally strong distribution channel in the northern hemisphere, and this is already starting to pay dividends in terms of revenues and market penetration,” said Paul Kinnon, CEO of ZyGEM. “These agreements also give us an ideal channel to promote ZyGEM’s planned new products as they are released over the course of the year.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.